Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
A phase 1/2 trial of ASTX660 in non-Hodgkin lymphoma, run by Taiho Oncology, Inc., active and no longer recruiting.
Overview
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas is a phase 1/2 interventional study registered as NCT02503423 by Taiho Oncology, Inc., with 253 participants enrolled, started 2015-07-14 and due to reach its primary completion in 2022-10. Interventions recorded: ASTX660.
Similar pages
not linked directly; found by shared links- TrialStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.